GlobeNewswire Inc | Dec 23, 2020 04:01PM EST

December 23, 2020

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference.

H.C. WainwrightBioconnect 2021 ConferenceDate:Monday, January 11, 2021Time:6:00 am ET(access to on demand webcast begins)

39^th Annual J.P. Morgan Healthcare ConferenceDate:Thursday, January 14, 2021Time:8:20 am ET

To access the webcast presentations, or the subsequent archived recordings, please visit the Investors section of the Ziopharm website atwww.ziopharm.com.

About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand others. For more information, please visitwww.ziopharm.com.

Investor Relations Contacts:Adam D. Levy, PhD, MBAEVP, Investor Relations and Corporate Communications(508) 552-9255alevy@ziopharm.com

Media Relations Contact:LifeSci Communications:Patrick BurseyT: 646.876.4932E: pbursey@lifescicomms.com